[1]Patent:WO2005/77945,2005,A2,.Locationinpatent:Page/Pagecolumn52
[2]Patent:US2009/118297,2009,A1,.Locationinpatent:Page/Pagecolumn32-33
[1]Patent:WO2005/77945,2005,A2,.Locationinpatent:Page/Pagecolumn58-59
[2]Patent:WO2007/35874,2007,A1,.Locationinpatent:Page/Pagecolumn57-58
[3]Patent:CN103880833,2018,B,.Locationinpatent:Paragraph0081-0104
[1]SyntheticCommunications,2017,vol.47,#17,p.1610-1621
[1]SyntheticCommunications,2017,vol.47,#17,p.1610-1621
[2]SyntheticCommunications,2017,vol.47,#17,p.1610-1621
[1]SyntheticCommunications,2017,vol.47,#17,p.1610-1621
[2]SyntheticCommunications,2017,vol.47,#17,p.1610-1621
[1]Patent:WO2005/77945,2005,A2.Locationinpatent:Page/Pagecolumn52
[2]Patent:US2009/118297,2009,A1.Locationinpatent:Page/Pagecolumn32-33
[1]Patent:WO2005/77945,2005,A2.Locationinpatent:Page/Pagecolumn58-59
[2]Patent:WO2007/35874,2007,A1.Locationinpatent:Page/Pagecolumn57-58
[3]Patent:CN103880833,2018,B.Locationinpatent:Paragraph0081-0104
[1]Patent:US2009/118297,2009,A1.Locationinpatent:Page/Pagecolumn33
[2]Patent:US2009/118297,2009,A1.Locationinpatent:Page/Pagecolumn33
[1]SyntheticCommunications,2017,vol.47,p.1610-1621
[1]SyntheticCommunications,2017,vol.47,p.1610-1621
[2]SyntheticCommunications,2017,vol.47,p.1610-1621
Title: High-mobility group box 1 protein-mediated necroptosis contributes to dasatinib-induced cardiotoxicity.
Journal: Toxicology letters 20181015
Title: The Use of Human Liver Cell Model and Cytochrome P450 Substrate-Inhibitor Panel for Studies of Dasatinib and Warfarin Interactions.
Journal: Bulletin of experimental biology and medicine 20170201
Title: Prolonged and tunable residence time using reversible covalent kinase inhibitors.
Journal: Nature chemical biology 20150701
Title: Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
Journal: Leukemia 20150401
Title: The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.
Journal: The Biochemical journal 20150115
Title: The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patients.
Journal: AIDS (London, England) 20140114
Title: Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20130501
Title: MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia.
Journal: PloS one 20130101
Title: Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.
Journal: Leukemia & lymphoma 20121201
Title: A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo.
Journal: International journal of cancer 20121115
Title: Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells.
Journal: Stem cells and development 20121101
Title: Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.
Journal: Experimental hematology 20121101
Title: Dasatinib inhibits leukaemic cell survival by decreasing PRH/Hhex phosphorylation resulting in increased repression of VEGF signalling genes.
Journal: Leukemia research 20121101
Title: Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.
Journal: Expert opinion on pharmacotherapy 20121101
Title: Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
Journal: American journal of hematology 20121101
Title: Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells.
Journal: Cancer letters 20121028
Title: Amyloid-β oligomers stimulate microglia through a tyrosine kinase dependent mechanism.
Journal: Neurobiology of aging 20121001
Title: Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.
Journal: Leukemia 20121001
Title: Philadelphia-positive acute lymphoblastic leukemia: current treatment options.
Journal: Current oncology reports 20121001
Title: Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Journal: Gynecologic oncology 20121001
Title: Chronic myeloid leukemia: state of the art in 2012.
Journal: Current oncology reports 20121001
Title: A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20121001
Title: Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.
Journal: Molecular cancer therapeutics 20121001
Title: Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.
Journal: Blood 20120927
Title: Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.
Journal: International journal of cancer 20120915
Title: In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia.
Journal: Pediatric blood & cancer 20120901
Title: Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.
Journal: European journal of clinical investigation 20120901
Title: Phosphosignature predicts dasatinib response in non-small cell lung cancer.
Journal: Molecular & cellular proteomics : MCP 20120901
Title: Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.
Journal: International journal of hematology 20120901
Title: New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
Journal: Drugs of today (Barcelona, Spain : 1998) 20120901
Title: Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120815
Title: Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.
Journal: Investigational new drugs 20120801
Title: Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications.
Journal: Leukemia & lymphoma 20120801
Title: A dramatic fetal outcome following transplacental transfer of dasatinib.
Journal: Anti-cancer drugs 20120801
Title: Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A.
Journal: Experimental hematology 20120801
Title: Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification.
Journal: Pediatric blood & cancer 20120801
Title: A sharp fluctuation in peripheral blood cells shortly after dasatinib administration.
Journal: International journal of hematology 20120801
Title: Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.
Journal: Blood 20120719
Title: The role of focal adhesion kinase catalytic activity on the proliferation and migration of squamous cell carcinoma cells.
Journal: International journal of cancer 20120715
Title: Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.
Journal: Blood 20120712
Title: Talc crystals in pleurodesis-associated talc granuloma.
Journal: Diagnostic cytopathology 20120701
Title: Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons.
Journal: Leukemia & lymphoma 20120701
Title: Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors.
Journal: Leukemia & lymphoma 20120701
Title: Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia.
Journal: Leukemia & lymphoma 20120701
Title: Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
Journal: Haematologica 20120701
Title: Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.
Journal: Cancer letters 20120701
Title: Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Journal: Journal of neuro-oncology 20120701
Title: Towards a need to a 'biological Sokal risk' in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia.
Journal: Leukemia research 20120701
Title: Design, synthesis and antiproliferative activity of 2-acetamidothiazole-5-carboxamide derivatives.
Journal: Medicinal chemistry (Shariqah (United Arab Emirates)) 20120701
Title: Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120701
Title: Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A.
Journal: Antiviral research 20120701
Title: A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
Journal: Current medical research and opinion 20120701
Title: Dasatinib enhances the expansion of CD56+CD3- NK cells from cord blood.
Journal: Blood 20120621
Title: Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes.
Journal: Toxicology and applied pharmacology 20120615
Title: Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.
Journal: Investigational new drugs 20120601
Title: Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells.
Journal: Leukemia 20120601
Title: Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib.
Journal: Leukemia & lymphoma 20120601
Title: Clinical trials in chronic myeloid leukemia.
Journal: Current hematologic malignancy reports 20120601
Title: Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
Journal: British journal of haematology 20120601
Title: Role of Src tyrosine kinases in experimental pulmonary hypertension.
Journal: Arteriosclerosis, thrombosis, and vascular biology 20120601
Title: Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells.
Journal: Cellular signalling 20120601
Title: Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
Journal: Neoplasia (New York, N.Y.) 20120601
Title: Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
Journal: Science translational medicine 20120530
Title: Dasatinib inhibits proinflammatory functions of mature human neutrophils.
Journal: Blood 20120524
Title: The shady side of dasatinib.
Journal: Blood 20120524
Title: Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120515
Title: Global tyrosine kinome profiling of human thyroid tumors identifies Src as a promising target for invasive cancers.
Journal: Biochemical and biophysical research communications 20120511
Title: EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
Journal: Blood 20120510
Title: Incorporation and controlled release of silyl ether prodrugs from PRINT nanoparticles.
Journal: Journal of the American Chemical Society 20120509
Title: Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer.
Journal: International journal of radiation oncology, biology, physics 20120501
Title: Novel molecular targets for the therapy of castration-resistant prostate cancer.
Journal: European urology 20120501
Title: MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib.
Journal: British journal of haematology 20120501
Title: Second-generation tyrosine kinase inhibitors as first-line treatment strategy in newly diagnosed chronic phase chronic myeloid leukemia patients.
Journal: Current cancer drug targets 20120501
Title: Bilateral subdural hemorrhage as a serious adverse event of dasatinib in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Journal: International journal of hematology 20120501
Title: Double-edged sword of the new cancer therapeutics.
Journal: Circulation 20120501
Title: Pulmonary arterial hypertension in patients treated by dasatinib.
Journal: Circulation 20120501
Title: Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study.
Journal: International journal of hematology 20120501
Title: Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Journal: International journal of cancer 20120415
Title: Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Journal: Blood 20120412
Title: Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.
Journal: Cancer chemotherapy and pharmacology 20120401
Title: Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120401
Title: BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Journal: Experimental and molecular pathology 20120401
Title: Intracellular protein trafficking kinetics in chronic myeloid leukemia stem cells using a microfluidic platform.
Journal: Integrative biology : quantitative biosciences from nano to macro 20120401
Title: Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120401
Title: Chronic myelogenous leukemia for primary care physicians.
Journal: Disease-a-month : DM 20120401
Title: CML treatment in Asia-Pacific region.
Journal: Hematology (Amsterdam, Netherlands) 20120401
Title: An update on dual Src/Abl inhibitors.
Journal: Future medicinal chemistry 20120401
Title: [Treatment with a tyrosine-kinase inhibitor of for c-KIT mutation and AML1-ETO double positive refractory acute myeloid leukemia].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20120401
Title: NICE backs leukaemia drug after manufacturer drops price.
Journal: BMJ (Clinical research ed.) 20120322
Title: Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death.
Journal: Oncogene 20120308
Title: Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.
Journal: Blood 20120308
Title: Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Journal: Blood 20120308
Title: Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia.
Journal: Leukemia & lymphoma 20120301
Title: Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation.
Journal: Haematologica 20120301
Title: Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion.
Journal: Angiogenesis 20120301
Title: p38 MAPK inhibition suppresses the TLR-hypersensitive phenotype in FANCC- and FANCA-deficient mononuclear phagocytes.
Journal: Blood 20120301
Title: Hair depigmentation and vitiligo-like lesions in a leukaemic paediatric patient during chemotherapy with dasatinib.
Journal: Acta dermato-venereologica 20120301
Title: Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.
Journal: Blood 20120223
Title: Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes.
Journal: Journal of the American Chemical Society 20120215
Title: Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Journal: Blood 20120209
Title: HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC).
Journal: Journal of pharmaceutical and biomedical analysis 20120205
Title: Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Journal: Blood 20120202
Title: Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells.
Journal: Investigational new drugs 20120201
Title: Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging.
Journal: Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20120201
Title: Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.
Journal: Annals of hematology 20120201
Title: The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors.
Journal: Cancer immunology, immunotherapy : CII 20120201
Title: Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120201
Title: Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
Journal: Journal of cancer research and clinical oncology 20120201
Title: Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
Journal: Carcinogenesis 20120201
Title: Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
Journal: Clinical & experimental metastasis 20120201
Title: Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
Journal: Breast cancer research and treatment 20120201
Title: Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Journal: Current medical research and opinion 20120201
Title: Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Journal: Clinical therapeutics 20120201
Title: NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.
Journal: The Lancet. Oncology 20120201
Title: A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study.
Journal: Journal of pharmaceutical and biomedical analysis 20120125
Title: Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.
Journal: Cancer 20120115
Title: Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120115
Title: Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives.
Journal: Bioorganic & medicinal chemistry letters 20120115
Title: Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
Journal: British journal of cancer 20120103
Title: Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Journal: Clinical science (London, England : 1979) 20120101
Title: Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.
Journal: Leukemia 20120101
Title: Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
Journal: Journal of biochemistry 20120101
Title: Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.
Journal: Leukemia research 20120101
Title: Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.
Journal: Leukemia research 20120101
Title: Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
Journal: Cancer 20120101
Title: Compound immobilization and drug-affinity chromatography.
Journal: Methods in molecular biology (Clifton, N.J.) 20120101
Title: Dasatinib overrides imatinib resistance mediated by the F359I residue mutation in two patients with chronic myeloid leukemia.
Journal: Acta haematologica 20120101
Title: [Myeloproliferative neoplasms (including chronic myeloid leukemia)].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20120101
Title: Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
Journal: PloS one 20120101
Title: [Current therapy of chronic myeloid leukemia].
Journal: Duodecim; laaketieteellinen aikakauskirja 20120101
Title: Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.
Journal: PloS one 20120101
Title: Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
Journal: Health technology assessment (Winchester, England) 20120101
Title: Glucocorticosteroids rescue basophils from dasatinib-augmented immunoglobulin E-mediated histamine release.
Journal: International archives of allergy and immunology 20120101
Title: Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
Journal: Health technology assessment (Winchester, England) 20120101
Title: [Pregnancy outcome among patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20120101
Title: Metabolite profiling of dasatinib dosed to Wistar Han rats using automated dried blood spot collection.
Journal: Journal of pharmaceutical and biomedical analysis 20120101
Title: Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation.
Journal: Journal of hematology & oncology 20120101
Title: The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer.
Journal: Journal of translational medicine 20120101
Title: Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease.
Journal: Journal of neuroinflammation 20120101
Title: Optimizing second-line therapy for chronic myeloid leukemia.
Journal: Indian journal of cancer 20120101
Title: Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells.
Journal: Onkologie 20120101
Title: An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents.
Journal: Methods in molecular biology (Clifton, N.J.) 20120101
Title: Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.
Journal: Internal medicine (Tokyo, Japan) 20120101
Title: Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I.
Journal: BMC cancer 20120101
Title: Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus.
Journal: Internal medicine (Tokyo, Japan) 20120101
Title: Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.
Journal: Journal of clinical and experimental hematopathology : JCEH 20120101
Title: c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis.
Journal: PloS one 20120101
Title: Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Journal: Blood 20111215
Title: Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Journal: Cancer cell 20111213
Title: Dasatinib, imatinib and staurosporine capture compounds - Complementary tools for the profiling of kinases by Capture Compound Mass Spectrometry (CCMS).
Journal: Journal of proteomics 20111210
Title: Tyrosine kinase inhibitors in hematological malignancies.
Journal: Postepy higieny i medycyny doswiadczalnej (Online) 20111205
Title: A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20111201
Title: Dasatinib-induced rapid regression and complete molecular remission of multiple subcutaneous tumours presenting as relapsed chronic myeloid leukaemia after cord blood transplantation.
Journal: Leukemia research 20111201
Title: Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.
Journal: Cancer research 20111201
Title: When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20111201
Title: Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20111201
Title: The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis.
Journal: PLoS genetics 20111201
Title: Novel therapies for metastatic castrate-resistant prostate cancer.
Journal: Journal of the National Cancer Institute 20111116
Title: Crystal structure of the EphA4 protein tyrosine kinase domain in the apo- and dasatinib-bound state.
Journal: FEBS letters 20111116
Title: Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
Journal: Cancer 20111115
Title: Changes in tumor tissue organization in collagen-I sensitize cells to ionizing radiation in an ex vivo model of solid mammary tumor growth and local invasion.
Journal: Cell cycle (Georgetown, Tex.) 20111115
Title: Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response.
Journal: Blood 20111110
Title: Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111110
Title: Significance of ER-Src axis in hormonal therapy resistance.
Journal: Breast cancer research and treatment 20111101
Title: A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes.
Journal: Annals of hematology 20111101
Title: Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Journal: Leukemia & lymphoma 20111101
Title: Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors.
Journal: Cancer science 20111101
Title: Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features.
Journal: Haematologica 20111101
Title: X-ray crystal structure of bone marrow kinase in the x chromosome: a Tec family kinase.
Journal: Chemical biology & drug design 20111101
Title: A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20111101
Title: Coexistence of translocation(1,19) and the Philadelphia chromosome in a child's first presentation of chronic myeloid leukemia in blast crisis treated with dasatinib.
Journal: Pediatric hematology and oncology 20111101
Title: Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20111101
Title: AHI1 gene expression levels and BCR-ABL1 T315I mutations in chronic myeloid leukemia patients.
Journal: Hematology (Amsterdam, Netherlands) 20111101
Title: Effectiveness of dasatinib in relapsed CNS, Ph+ ALL that is refractory to radiochemotherapy plus imatinib: a case report.
Journal: Clinical advances in hematology & oncology : H&O 20111101
Title: Recommendations for the management of adult chronic myeloid leukaemia in South Africa.
Journal: South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20111101
Title: Src: a potential target for the treatment of triple-negative breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20111001
Title: Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study.
Journal: British journal of haematology 20111001
Title: Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.
Journal: Leukemia 20111001
Title: Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1.
Journal: Leukemia & lymphoma 20111001
Title: Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.
Journal: Haematologica 20111001
Title: Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20111001
Title: Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.
Journal: International journal of hematology 20111001
Title: Dasatinib: pulmonary arterial hypertension. French data.
Journal: Prescrire international 20111001
Title: [Roles of the 2nd generation TKIs for CML].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20111001
Title: Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.
Journal: Haematologica 20111001
Title: Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
Journal: Clinical advances in hematology & oncology : H&O 20111001
Title: The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
Journal: Journal of the National Cancer Institute 20110921
Title: Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110915
Title: Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Journal: Drugs 20110910
Title: Secretome compartment is a valuable source of biomarkers for cancer-relevant pathways.
Journal: Journal of proteome research 20110902
Title: Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20110901
Title: Nilotinib and dasatinib first-line: are we ready for imatinib replacement?
Journal: Leukemia research 20110901
Title: Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Journal: Leukemia research 20110901
Title: Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Journal: Current hematologic malignancy reports 20110901
Title: Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110901
Title: Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.
Journal: Leukemia research 20110901
Title: Advanced age and prognosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Journal: Leukemia research 20110901
Title: Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
Journal: Cell cycle (Georgetown, Tex.) 20110901
Title: Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism.
Journal: Journal of cell science 20110901
Title: [Thermostability and crystal structure of anticancer drug dasatinib].
Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20110901
Title: KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Journal: Blood 20110818
Title: Targeting SRC in mucinous ovarian carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110815
Title: Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110810
Title: Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure.
Journal: Journal of neuro-oncology 20110801
Title: The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma.
Journal: Pigment cell & melanoma research 20110801
Title: Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.
Journal: Cancer biology & therapy 20110801
Title: Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells.
Journal: Cell cycle (Georgetown, Tex.) 20110801
Title: [A therapeutic improvement: second generation tyrosine kinase inhibitors (TKI 2) in the treatment of chronic myelogenous leukemia].
Journal: Bulletin du cancer 20110801
Title: Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion.
Journal: Leukemia & lymphoma 20110701
Title: Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
Journal: Leukemia & lymphoma 20110701
Title: F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
Journal: Leukemia research 20110701
Title: Synthesis and biological activities of 2-amino-thiazole-5-carboxylic acid phenylamide derivatives.
Journal: Archiv der Pharmazie 20110701
Title: Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
Journal: The European respiratory journal 20110701
Title: [TKI therapy for CML].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20110701
Title: [Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20110701
Title: HOXC11-SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib.
Journal: British journal of cancer 20110628
Title: In situ kinase profiling reveals functionally relevant properties of native kinases.
Journal: Chemistry & biology 20110624
Title: How does a drug molecule find its target binding site?
Journal: Journal of the American Chemical Society 20110622
Title: Pan-Src family kinase inhibitors replace Sox2 during the direct reprogramming of somatic cells.
Journal: Angewandte Chemie (International ed. in English) 20110614
Title: Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110610
Title: New drugs for chronic myelogenous leukemia.
Journal: Current hematologic malignancy reports 20110601
Title: Chronic myelogenous leukemia: monitoring response to therapy.
Journal: Current hematologic malignancy reports 20110601
Title: Predicting the response of CML patients to tyrosine kinase inhibitor therapy.
Journal: Current hematologic malignancy reports 20110601
Title: Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
Journal: European journal of haematology 20110601
Title: Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials.
Journal: Current medical research and opinion 20110601
Title: Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20110601
Title: Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.
Journal: International journal of hematology 20110601
Title: Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110601
Title: Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
Journal: The oncologist 20110601
Title: A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.
Journal: Science translational medicine 20110601
Title: Dasatinib for the treatment of chronic myeloid leukemia.
Journal: Expert review of hematology 20110601
Title: Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients.
Journal: Expert review of hematology 20110601
Title: Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation.
Journal: Clinical lymphoma, myeloma & leukemia 20110601
Title: Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
Journal: Cancer 20110515
Title: A phase 2 trial of dasatinib in advanced melanoma.
Journal: Cancer 20110515
Title: Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.
Journal: Blood 20110512
Title: Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum.
Journal: Science (New York, N.Y.) 20110506
Title: Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110501
Title: Interpretation of cytogenetic and molecular results in patients treated for CML.
Journal: Blood reviews 20110501
Title: Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?
Journal: The oncologist 20110501
Title: The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.
Journal: Leukemia & lymphoma 20110501
Title: Current status of SRC inhibitors in solid tumor malignancies.
Journal: The oncologist 20110501
Title: Novel nephrotoxins.
Journal: Advances in chronic kidney disease 20110501
Title: Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
Journal: Urology 20110501
Title: Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection.
Journal: Journal of chromatographic science 20110501
Title: [Indications and current development of new targeted therapies in pediatric oncology].
Journal: Bulletin du cancer 20110501
Title: [Hemorrhagic colitis caused by dasatinib following cytomegalovirus enterocolitis in a patient with chronic myelogenous leukemia in the second chronic phase].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20110501
Title: Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Journal: Cancer discovery 20110403
Title: An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.
Journal: International journal of laboratory hematology 20110401
Title: Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.
Journal: Gynecologic oncology 20110401
Title: Dasatinib: an anti-tumour agent via Src inhibition.
Journal: Current drug targets 20110401
Title: 2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines.
Journal: Journal of proteomics 20110401
Title: Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.
Journal: Pediatric blood & cancer 20110401
Title: Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110401
Title: In vitro studies of dasatinib, its targets and predictors of sensitivity.
Journal: Pigment cell & melanoma research 20110401
Title: Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals.
Journal: British journal of haematology 20110401
Title: Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia.
Journal: American journal of hematology 20110401
Title: Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
Journal: American journal of hematology 20110401
Title: The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).
Journal: Haematologica 20110401
Title: Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors.
Journal: Clinical lymphoma, myeloma & leukemia 20110401
Title: Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Journal: Blood 20110331
Title: The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer.
Journal: Journal of the National Cancer Institute 20110302
Title: Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
Journal: Cancer 20110301
Title: Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.
Journal: Haematologica 20110301
Title: Navigating the road toward optimal initial therapy for chronic myeloid leukemia.
Journal: Current opinion in hematology 20110301
Title: [Chronic myeloid leukemia. Diagnostics, therapy and future strategy].
Journal: Der Internist 20110301
Title: Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110301
Title: Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.
Journal: Haematologica 20110301
Title: Targeting the DFG-in kinase conformation: a new trend emerging from a patent analysis.
Journal: Future medicinal chemistry 20110301
Title: Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia.
Journal: Pharmacogenomics 20110301
Title: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.
Journal: Blood 20110224
Title: Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
Journal: Journal of the National Cancer Institute 20110216
Title: Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.
Journal: International journal of cancer 20110215
Title: Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.
Journal: Cancer 20110215
Title: Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110215
Title: Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
Journal: Blood 20110210
Title: Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.
Journal: Blood 20110210
Title: Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Journal: Oncogene 20110203
Title: Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Journal: Leukemia 20110201
Title: Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110201
Title: Invasive prostate carcinoma driven by c-Src and androgen receptor synergy.
Journal: Cancer research 20110201
Title: Excellent response to dasatinib of childhood Philadelphia positive intracranial acute lymphoblastic leukaemia tumours.
Journal: British journal of haematology 20110201
Title: The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients.
Journal: Expert opinion on investigational drugs 20110201
Title: Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53.
Journal: Cancer research 20110201
Title: Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110201
Title: Response to combined molecular targeting: defining the role of P-STAT3.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110201
Title: A quantitative, facile, and high-throughput image-based cell migration method is a robust alternative to the scratch assay.
Journal: Journal of biomolecular screening 20110201
Title: [Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib].
Journal: Annales de dermatologie et de venereologie 20110201
Title: Pharmacotherapy for chronic myelogenous leukemia: a case-based approach.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN 20110201
Title: Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110115
Title: Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.
Journal: Cell cycle (Georgetown, Tex.) 20110115
Title: New insights into small-molecule inhibitors of Bcr-Abl.
Journal: Medicinal research reviews 20110101
Title: Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
Journal: Archives of gynecology and obstetrics 20110101
Title: p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes.
Journal: Leukemia research 20110101
Title: Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.
Journal: Leukemia research 20110101
Title: The role of p53 and autophagy in Dasatinib resistance of CLL lymphocytes.
Journal: Leukemia research 20110101
Title: Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias?
Journal: Leukemia research 20110101
Title: A magnetic bead-based protein kinase assay with dual detection techniques.
Journal: Analytical biochemistry 20110101
Title: Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib.
Journal: Leukemia research 20110101
Title: Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.
Journal: Haematologica 20110101
Title: On the assessment of dasatinib-induced autophagy in CLL.
Journal: Leukemia research 20110101
Title: p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells.
Journal: Carcinogenesis 20110101
Title: Novel variant Ph translocation t(9;22;11)(q34;q11.2;p15)inv(9)(p13q34) in chronic myeloid leukemia involving a one-step mechanism.
Journal: Cytogenetic and genome research 20110101
Title: Allosteric interactions between the myristate- and ATP-site of the Abl kinase.
Journal: PloS one 20110101
Title: Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
Journal: BMC pulmonary medicine 20110101
Title: Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
Journal: The Journal of international medical research 20110101
Title: Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line.
Journal: Journal of hematology & oncology 20110101
Title: Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
Journal: Clinical laboratory 20110101
Title: Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib.
Journal: Dermatologic therapy 20110101
Title: Targeted drug therapy: the platelet side.
Journal: Platelets 20110101
Title: A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients.
Journal: Journal of chromatographic science 20110101
Title: Effects of BCR-ABL inhibitors on anti-tumor immunity.
Journal: Current medicinal chemistry 20110101
Title: The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.
Journal: PloS one 20110101
Title: New drugs in medical oncology: new difficulties to distinguish drug-induced side effects from cancer complications: a case-report.
Journal: Acta clinica Belgica 20110101
Title: EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.
Journal: Blood 20101223
Title: Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.
Journal: Blood 20101216
Title: Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.
Journal: Cancer letters 20101208
Title: Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
Journal: Medical oncology (Northwood, London, England) 20101201
Title: Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
Journal: Therapeutic drug monitoring 20101201
Title: Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.
Journal: Current medical research and opinion 20101201
Title: Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.
Journal: American journal of hematology 20101201
Title: Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options.
Journal: Expert review of hematology 20101201
Title: Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia.
Journal: Clinical lymphoma, myeloma & leukemia 20101201
Title: [A case of t(3;3)(q21;q26.2) associated with severe multilineage dysplasia and multi-drug resistance in blastic crisis of chronic myelogenous leukemia].
Journal: The Korean journal of laboratory medicine 20101201
Title: How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia.
Journal: Blood 20101104
Title: The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
Journal: International journal of cancer 20101101
Title: Dasatinib induces autophagic cell death in human ovarian cancer.
Journal: Cancer 20101101
Title: Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinib.
Journal: European journal of haematology 20101101
Title: Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.
Journal: European journal of haematology 20101101
Title: Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20101101
Title: Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.
Journal: Molecular cancer therapeutics 20101101
Title: Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia.
Journal: Thyroid : official journal of the American Thyroid Association 20101101
Title: Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9.
Journal: Cancer research 20101101
Title: [Effect of low-dose dasatinib in an elderly patient with chronic myelogenous leukemia (CML)].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20101101
Title: [Chronic myeloid leukemia and targeted therapies: too many choices?].
Journal: Medecine sciences : M/S 20101101
Title: Second-generation BCR-ABL kinase inhibitors in CML.
Journal: The New England journal of medicine 20101021
Title: Second-generation BCR-ABL kinase inhibitors in CML.
Journal: The New England journal of medicine 20101021
Title: Second-generation BCR-ABL kinase inhibitors in CML.
Journal: The New England journal of medicine 20101021
Title: Second-generation BCR-ABL kinase inhibitors in CML.
Journal: The New England journal of medicine 20101021
Title: Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101020
Title: Expanding the diversity of allosteric bcr-abl inhibitors.
Journal: Journal of medicinal chemistry 20101014
Title: Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy.
Journal: Blood 20101007
Title: Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.
Journal: Cancer treatment reviews 20101001
Title: H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.
Journal: Experimental hematology 20101001
Title: Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?
Journal: European journal of clinical investigation 20101001
Title: Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo.
Journal: Cancer biology & therapy 20101001
Title: Src family kinases are essential for primary aggregation by G(i) -coupled receptors.
Journal: Journal of thrombosis and haemostasis : JTH 20101001
Title: Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib.
Journal: Leukemia 20101001
Title: Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation.
Journal: International journal of hematology 20101001
Title: Hemorrhagic colonic ulcers caused by dasatinib for chronic myelogenous leukemia.
Journal: International journal of hematology 20101001
Title: Dasatinib is effective against optic nerve infiltration of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Journal: Leukemia & lymphoma 20101001
Title: Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
Journal: Seminars in hematology 20101001
Title: Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
Journal: Nature reviews. Clinical oncology 20101001
Title: [SRC kinases in tumor therapy].
Journal: Medizinische Klinik (Munich, Germany : 1983) 20101001
Title: First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
Journal: Blood 20100923
Title: Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
Journal: Journal of the National Cancer Institute 20100922
Title: Multicolor monitoring of dysregulated protein kinases in chronic myelogenous leukemia.
Journal: ACS chemical biology 20100917
Title: Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.
Journal: Cancer research 20100915
Title: Allosteric inhibition of BCR-ABL.
Journal: Cell cycle (Georgetown, Tex.) 20100915
Title: Inhibition of immune responses by Dasatinib may account for its different effects on neuroblastoma between in vitro and in vivo.
Journal: International journal of cancer 20100901
Title: Development of severe sclerotic chronic GVHD during treatment with dasatinib.
Journal: Bone marrow transplantation 20100901
Title: Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.
Journal: Cell death and differentiation 20100901
Title: Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor.
Journal: Leukemia research 20100901
Title: Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases.
Journal: Annals of hematology 20100901
Title: Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression.
Journal: Leukemia research 20100901
Title: A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.
Journal: Leukemia research 20100901
Title: Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib.
Journal: Leukemia & lymphoma 20100901
Title: Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines.
Journal: International journal of oncology 20100901
Title: Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.
Journal: Cancer genetics and cytogenetics 20100901
Title: Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
Journal: Expert opinion on drug safety 20100901
Title: Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib.
Journal: Molecular cancer research : MCR 20100901
Title: Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
Journal: Cancer 20100815
Title: Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
Journal: Blood 20100805
Title: A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia.
Journal: Leukemia research 20100801
Title: The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100801
Title: Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors.
Journal: European journal of haematology 20100801
Title: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20100801
Title: Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
Journal: British journal of haematology 20100801
Title: Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Journal: Expert opinion on investigational drugs 20100801
Title: Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
Journal: Acta oncologica (Stockholm, Sweden) 20100801
Title: Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
Journal: Molecular cancer therapeutics 20100801
Title: [Development of ABL tyrosine kinase inhibitors].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20100801
Title: Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.
Journal: Cancer cell 20100713
Title: Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment.
Journal: Cell death and differentiation 20100701
Title: Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma.
Journal: Gastroenterology 20100701
Title: Pleural effusions due to dasatinib.
Journal: Current opinion in pulmonary medicine 20100701
Title: MASPECTRAS 2: An integration and analysis platform for proteomic data.
Journal: Proteomics 20100701
Title: Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro.
Journal: Leukemia 20100701
Title: Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells.
Journal: Leukemia 20100701
Title: Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
Journal: Leukemia 20100701
Title: Even better kinase inhibitors for chronic myeloid leukemia.
Journal: The New England journal of medicine 20100617
Title: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Journal: The New England journal of medicine 20100617
Title: Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
Journal: Oncogene 20100603
Title: Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Journal: Oncogene 20100603
Title: Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Journal: Hematological oncology 20100601
Title: Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib.
Journal: Leukemia research 20100601
Title: Achievement of complete donor-type chimerism and remission with dasatinib in Philadelphia chromosome-positive ALL relapsing after allogeneic transplantation.
Journal: Bone marrow transplantation 20100601
Title: Dasatinib: is it all in the dose?
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20100601
Title: Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion.
Journal: International journal of hematology 20100601
Title: Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
Journal: Cancer genetics and cytogenetics 20100601
Title: Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
Journal: Cancer 20100601
Title: First-line therapy for chronic myeloid leukemia: new horizons and an update.
Journal: Clinical lymphoma, myeloma & leukemia 20100601
Title: ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.
Journal: Molecular cancer therapeutics 20100601
Title: How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Journal: Clinical lymphoma, myeloma & leukemia 20100601
Title: Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective.
Journal: Clinical lymphoma, myeloma & leukemia 20100601
Title: Role of Pten in leukemia stem cells.
Journal: Oncotarget 20100601
Title: Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors--the first molecular targeted treatment.
Journal: Journal of medicine and life 20100515
Title: Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma.
Journal: Leukemia research 20100501
Title: Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Journal: Acta oncologica (Stockholm, Sweden) 20100501
Title: The combination of thymosin and methylprednisolone for the treatment of a patient with colonic ulcers, subcutaneous nodules, and pleural effusion after dasatinib treatment for chronic myeloid leukemia.
Journal: Leukemia & lymphoma 20100501
Title: Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias.
Journal: Molecular cancer therapeutics 20100501
Title: Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling.
Journal: Molecular cancer therapeutics 20100501
Title: Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
Journal: Molecular cancer therapeutics 20100501
Title: Development of candidate genomic markers to select breast cancer patients for dasatinib therapy.
Journal: Molecular cancer therapeutics 20100501
Title: Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.
Journal: Clinical therapeutics 20100501
Title: Humulane and germacrane sesquiterpenes from Ferula lycia.
Journal: Journal of natural products 20100423
Title: Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.
Journal: Leukemia research 20100401
Title: Allogenic bone marrow transplantation with fludarabine/busulfan16 conditioning regimen and dasatinib maintenance therapy for elderly Philadelphia-positive acute/advanced leukemia patients.
Journal: Leukemia research 20100401
Title: ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.
Journal: Leukemia 20100401
Title: Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.
Journal: Leukemia 20100401
Title: Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.
Journal: Leukemia 20100401
Title: Lck is a key target of imatinib and dasatinib in T-cell activation.
Journal: Leukemia 20100401
Title: A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.
Journal: Nature chemical biology 20100401
Title: Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase.
Journal: International journal of hematology 20100401
Title: Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.
Journal: Leukemia & lymphoma 20100401
Title: Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
Journal: Blood 20100318
Title: Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors.
Journal: Cancer 20100315
Title: Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Journal: Cancer 20100315
Title: LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer.
Journal: Cancer research 20100315
Title: Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100310
Title: Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy.
Journal: Leukemia 20100301
Title: Dasatinib promotes ATRA-induced differentiation of AML cells.
Journal: Leukemia 20100301
Title: Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
Journal: Leukemia & lymphoma 20100301
Title: Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment.
Journal: Clinical chemistry 20100301
Title: Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases.
Journal: Protein science : a publication of the Protein Society 20100301
Title: A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100301
Title: Dasatinib in solid tumors.
Journal: Expert opinion on investigational drugs 20100301
Title: Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
Journal: American journal of hematology 20100301
Title: Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen?
Journal: American journal of hematology 20100301
Title: Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
Journal: Bioorganic & medicinal chemistry 20100301
Title: [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20100301
Title: Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100215
Title: SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.
Journal: Blood 20100204
Title: Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
Journal: Leukemia research 20100201
Title: Dasatinib may not suppress the GVL effect of donor lymphocyte infusions for CML.
Journal: Bone marrow transplantation 20100201
Title: Abdominal pain in a patient with acute lymphoblastic leukaemia.
Journal: Annals of hematology 20100201
Title: Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Journal: Haematologica 20100201
Title: Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Journal: Leukemia & lymphoma 20100201
Title: AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance.
Journal: Chemical biology & drug design 20100201
Title: Targeting the tumor microenvironment with SRC kinase inhibition.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100201
Title: Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100201
Title: Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
Journal: Haematologica 20100201
Title: Reversible cardiotoxicity with tyrosine kinase inhibitors.
Journal: Clinical advances in hematology & oncology : H&O 20100201
Title: Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100120
Title: Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.
Journal: Cancer 20100115
Title: Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20100115
Title: Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Journal: Leukemia 20100101
Title: Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
Journal: Cancer science 20100101
Title: Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias.
Journal: Acta oncologica (Stockholm, Sweden) 20100101
Title: Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.
Journal: Cytotherapy 20100101
Title: Successful prior treatment with dasatinib followed by stem cell transplantation in a patient with CML in blastic crisis with a BCR-ABL mutation.
Journal: International journal of hematology 20100101
Title: Dasatinib.
Journal: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101
Title: Acute renal failure under dasatinib therapy.
Journal: Renal failure 20100101
Title: A case of acute colitis with severe rectal bleeding in a patient with chronic myeloid leukemia after dasatinib use.
Journal: Acta haematologica 20100101
Title: Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Journal: Swiss medical weekly 20100101
Title: Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.
Journal: Neoplasma 20100101
Title: Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.
Journal: Molecular cancer 20100101
Title: The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts.
Journal: BMC cancer 20100101
Title: Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts.
Journal: Molecular cancer 20100101
Title: Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia.
Journal: Acta haematologica 20100101
Title: Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia.
Journal: Acta haematologica 20100101
Title: Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option.
Journal: Molecular cancer 20100101
Title: Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib.
Journal: Acta haematologica 20100101
Title: Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.
Journal: Molecular cancer 20100101
Title: Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype.
Journal: BMC cancer 20100101
Title: Targeted inhibition of kinases in cancer therapy.
Journal: The Mount Sinai journal of medicine, New York 20100101
Title: First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
Journal: Journal of hematology & oncology 20100101
Title: Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment.
Journal: Clinical & developmental immunology 20100101
Title: Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Journal: Cancer biomarkers : section A of Disease markers 20100101
Title: Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester.
Journal: BMJ case reports 20100101
Title: Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Journal: Blood 20091224
Title: Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
Journal: Veterinary immunology and immunopathology 20091215
Title: Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091210
Title: Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.
Journal: Blood 20091203
Title: Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib.
Journal: Pediatric blood & cancer 20091201
Title: Dasatinib after allogeneic stem cell transplantation in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Journal: Pediatric blood & cancer 20091201
Title: Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model.
Journal: International journal of cancer 20091201
Title: Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics.
Journal: Molecular & cellular proteomics : MCP 20091201
Title: Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.
Journal: Leukemia & lymphoma 20091201
Title: Clinical pharmacokinetics of tyrosine kinase inhibitors.
Journal: Cancer treatment reviews 20091201
Title: Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.
Journal: European journal of clinical investigation 20091201
Title: Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo.
Journal: Experimental hematology 20091201
Title: Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091201
Title: Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20091201
Title: Hematology: dasatinib regimens for patients with chronic myeloid leukemia.
Journal: Nature reviews. Clinical oncology 20091201
Title: Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials.
Journal: Clinical lymphoma & myeloma 20091201
Title: p38 in chronic myelogenous leukemia: a target and a possible biomarker.
Journal: Leukemia & lymphoma 20091201
Title: Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.
Journal: Leukemia & lymphoma 20091201
Title: Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
Journal: British journal of cancer 20091117
Title: Systematically linking drug susceptibility to cancer genome aberrations.
Journal: Cell cycle (Georgetown, Tex.) 20091115
Title: The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
Journal: Blood 20091112
Title: Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.
Journal: Journal of neuro-oncology 20091101
Title: Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery.
Journal: Leukemia research 20091101
Title: Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitro.
Journal: British journal of haematology 20091101
Title: Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20091101
Title: Dasatinib-induced pleural effusions: a lymphatic network disorder?
Journal: The American journal of the medical sciences 20091101
Title: Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation.
Journal: Cancer biology & therapy 20091101
Title: Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
Journal: Molecular cancer therapeutics 20091101
Title: Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.
Journal: Blood 20091015
Title: Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling.
Journal: Cancer letters 20091008
Title: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Journal: British journal of pharmacology 20091001
Title: Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20091001
Title: Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options.
Journal: Clinical journal of oncology nursing 20091001
Title: A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).
Journal: Haematologica 20091001
Title: BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
Journal: Hong Kong medical journal = Xianggang yi xue za zhi 20091001
Title: Lasker Awards and papal portraiture: turning fields upside down.
Journal: Nature medicine 20091001
Title: [Clinical use of tyrosine kinase inhibitors for treatment of myeloid leukemias].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20091001
Title: [Clinical progress in chronic myelogenous leukemia].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20091001
Title: Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells.
Journal: Lab on a chip 20090921
Title: Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
Journal: Cancer 20090915
Title: Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Journal: Blood 20090910
Title: Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Journal: Blood 20090903
Title: Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
Journal: Blood 20090903
Title: Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?
Journal: Bone marrow transplantation 20090901
Title: Efficacy of dasatinib in conjunction with alpha-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia.
Journal: Leukemia 20090901
Title: P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
Journal: The Journal of pharmacology and experimental therapeutics 20090901
Title: Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.
Journal: Cancer 20090901
Title: A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Journal: Haematologica 20090901
Title: Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Journal: Leukemia 20090901
Title: Severe hemorrhagic colitis caused by dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Journal: Pediatric hematology and oncology 20090901
Title: Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?
Journal: Current oncology reports 20090901
Title: Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.
Journal: Cancer research 20090901
Title: Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia.
Journal: Haematologica 20090901
Title: The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment.
Journal: Molecular cancer research : MCR 20090901
Title: [Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia].
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20090901
Title: Transcriptional profiling of the dose response: a more powerful approach for characterizing drug activities.
Journal: PLoS computational biology 20090901
Title: The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.
Journal: Blood 20090827
Title: Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations.
Journal: Leukemia research 20090801
Title: Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
Journal: Leukemia 20090801
Title: t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis.
Journal: Cancer investigation 20090801
Title: Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment.
Journal: Cancer research 20090801
Title: Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
Journal: Molecular cancer therapeutics 20090801
Title: Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
Journal: British journal of cancer 20090721
Title: Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090720
Title: Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090715
Title: Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.
Journal: Blood 20090709
Title: Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells.
Journal: British journal of cancer 20090707
Title: Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro.
Journal: Digestive diseases and sciences 20090701
Title: Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Journal: Pediatric blood & cancer 20090701
Title: Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
Journal: Cancer 20090701
Title: Dasatinib-induced response in a rare case of chronic lymphocytic leukaemia associated with chronic myeloid leukaemia.
Journal: British journal of haematology 20090701
Title: Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients.
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20090701
Title: Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Journal: Blood 20090618
Title: New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090615
Title: Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.
Journal: Leukemia research 20090601
Title: Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia.
Journal: Leukemia research 20090601
Title: Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient.
Journal: Bone marrow transplantation 20090601
Title: Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia.
Journal: Leukemia 20090601
Title: Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
Journal: Cancer 20090601
Title: Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20090601
Title: Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Journal: British journal of haematology 20090601
Title: Dasatinib induces complete cytogenetic response and loss of F359C in an imatinib resistant chronic myelocytic leukemia patient.
Journal: American journal of hematology 20090601
Title: Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.
Journal: Journal of clinical pharmacology 20090601
Title: Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Journal: Melanoma research 20090601
Title: Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia.
Journal: International journal of hematology 20090601
Title: Chronic myelogenous leukaemia market.
Journal: Nature reviews. Drug discovery 20090601
Title: A once-daily dasatinib dosing strategy for chronic myeloid leukemia.
Journal: Clinical journal of oncology nursing 20090601
Title: Practical management of dasatinib for maximum patient benefit.
Journal: Clinical journal of oncology nursing 20090601
Title: Response dynamics in chronic-phase chronic myeloid leukemia.
Journal: Clinical lymphoma & myeloma 20090601
Title: First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults.
Journal: Current opinion in oncology 20090601
Title: Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Journal: Blood 20090521
Title: SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090515
Title: Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090515
Title: Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
Journal: Blood 20090514
Title: Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.
Journal: Leukemia research 20090501
Title: Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.
Journal: Leukemia research 20090501
Title: Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis.
Journal: Leukemia 20090501
Title: First-line therapy for chronic myeloid leukemia: Past, present, and future.
Journal: American journal of hematology 20090501
Title: Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
Journal: The Annals of pharmacotherapy 20090501
Title: Hydrophilic interaction liquid chromatography/tandem mass spectrometry for the simultaneous determination of dasatinib, imatinib and nilotinib in mouse plasma.
Journal: Rapid communications in mass spectrometry : RCM 20090501
Title: Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
Journal: The Journal of clinical investigation 20090501
Title: Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance.
Journal: Leukemia & lymphoma 20090501
Title: Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
Journal: Cancer research 20090501
Title: Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
Journal: Cancer research 20090501
Title: Genomic strategy for targeting therapy in castration-resistant prostate cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090420
Title: Dasatinib-induced restoration of donor chimerism in BCR-ABL1-positive ALL after failure of imatinib therapy and allo-SCT.
Journal: Bone marrow transplantation 20090401
Title: Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations.
Journal: Cancer 20090401
Title: Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
Journal: American journal of hematology 20090401
Title: Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Journal: International journal of hematology 20090401
Title: Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090401
Title: Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.
Journal: Cancer biology & therapy 20090401
Title: Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.
Journal: Current rheumatology reports 20090401
Title: Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib.
Journal: Cancer research 20090401
Title: Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Journal: Cancer control : journal of the Moffitt Cancer Center 20090401
Title: Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors.
Journal: Cancer control : journal of the Moffitt Cancer Center 20090401
Title: The toxicities of modern targeted therapies: learning from the price of progress.
Journal: Targeted oncology 20090401
Title: Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor.
Journal: Journal of drugs in dermatology : JDD 20090401
Title: Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
Journal: Leukemia & lymphoma 20090401
Title: Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
Journal: Targeted oncology 20090401
Title: Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Journal: Expert review of pharmacoeconomics & outcomes research 20090401
Title: Optimizing first-line therapy for patients with chronic myeloid leukemia.
Journal: Seminars in hematology 20090401
Title: Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia.
Journal: Seminars in hematology 20090401
Title: New directions in the treatment of imatinib failure and/or resistance.
Journal: Seminars in hematology 20090401
Title: Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20090301
Title: Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor.
Journal: Leukemia 20090301
Title: Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia.
Journal: Leukemia 20090301
Title: Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Journal: Leukemia 20090301
Title: Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding.
Journal: Cancer research 20090301
Title: New approved dasatinib regimen available for clinical use.
Journal: Expert review of anticancer therapy 20090301
Title: Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous leukemia: when to change? A perspective in 2009.
Journal: Current opinion in hematology 20090301
Title: Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
Journal: Leukemia research 20090201
Title: Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.
Journal: Experimental hematology 20090201
Title: Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells.
Journal: Experimental hematology 20090201
Title: Src as a therapeutic target in men with prostate cancer and bone metastases.
Journal: BJU international 20090201
Title: Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
Journal: Mayo Clinic proceedings 20090201
Title: Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
Journal: Molecular cancer therapeutics 20090201
Title: Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090120
Title: Dasatinib induces a response in chronic lymphocytic leukemia.
Journal: Blood 20090108
Title: Crystal structures of the Lyn protein tyrosine kinase domain in its Apo- and inhibitor-bound state.
Journal: The Journal of biological chemistry 20090102
Title: Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia.
Journal: Leukemia 20090101
Title: Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers.
Journal: Journal of immunological methods 20090101
Title: Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells.
Journal: British journal of haematology 20090101
Title: Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.
Journal: Haematologica 20090101
Title: Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors.
Journal: International journal of hematology 20090101
Title: Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.
Journal: Nature biotechnology 20090101
Title: Imatinib and its successors--how modern chemistry has changed drug development.
Journal: Current pharmaceutical design 20090101
Title: Dasatinib in relapsed or plateau-phase multiple myeloma.
Journal: Leukemia & lymphoma 20090101
Title: New dosing schedules of dasatinib for CML and adverse event management.
Journal: Journal of hematology & oncology 20090101
Title: The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2).
Journal: BMC structural biology 20090101
Title: Treatment selection after imatinib resistance in chronic myeloid leukemia.
Journal: Targeted oncology 20090101
Title: Tyrosine kinase inhibitors and solid tumours: case report and review of the literature.
Journal: Pharmacology 20090101
Title: Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.
Journal: Acta haematologica 20090101
Title: [Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase].
Journal: Terapevticheskii arkhiv 20090101
Title: Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.
Journal: Clinical lymphoma & myeloma 20090101
Title: The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.
Journal: Journal of hematology & oncology 20090101
Title: Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Journal: Hematology. American Society of Hematology. Education Program 20090101
Title: Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth.
Journal: Molecular cancer 20090101
Title: Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Journal: Blood 20081215
Title: In situ monitoring of bindings between dasatinib and its target protein kinases using magnetic nanoparticles in live cells.
Journal: Journal of the American Chemical Society 20081210
Title: Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
Journal: Cancer cell 20081209
Title: Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.
Journal: European journal of pharmacology 20081203
Title: Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Journal: Leukemia 20081201
Title: Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.
Journal: Leukemia 20081201
Title: Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20081201
Title: Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Journal: Cancer research 20081201
Title: Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
Journal: Cancer research 20081201
Title: Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.
Journal: British journal of haematology 20081201
Title: [Chronic myeloid leukemia 2008].
Journal: Medicina clinica 20081115
Title: Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Journal: Cancer chemotherapy and pharmacology 20081101
Title: Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib.
Journal: Leukemia research 20081101
Title: Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia.
Journal: Leukemia 20081101
Title: Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.
Journal: Blood 20081101
Title: Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20081101
Title: Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia.
Journal: Journal of clinical pharmacology 20081101
Title: Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
Journal: Molecular cancer research : MCR 20081101
Title: Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis.
Journal: European journal of clinical investigation 20081101
Title: Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].
Journal: Clinical advances in hematology & oncology : H&O 20081101
Title: Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Journal: Clinical advances in hematology & oncology : H&O 20081101
Title: Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.
Journal: Blood 20081015
Title: Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.
Journal: British journal of cancer 20081007
Title: Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib.
Journal: Leukemia research 20081001
Title: Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.
Journal: Experimental hematology 20081001
Title: Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens.
Journal: Experimental hematology 20081001
Title: Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.
Journal: Rheumatology (Oxford, England) 20081001
Title: Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20081001
Title: [Management of acute lymphoblastic leukemia].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20081001
Title: [Management of chronic myeloid leukemia].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20081001
Title: Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.
Journal: Molecular cancer therapeutics 20081001
Title: The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia.
Journal: Molecular oncology 20081001
Title: Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080915
Title: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20080901
Title: Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib.
Journal: Leukemia 20080901
Title: What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response.
Journal: Clinical advances in hematology & oncology : H&O 20080901
Title: [Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
Journal: Bulletin du cancer 20080901
Title: Dasatinib-induced lupus.
Journal: Lancet (London, England) 20080830
Title: Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
Journal: Blood 20080815
Title: Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib.
Journal: Blood 20080815
Title: The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.
Journal: Blood 20080815
Title: Successful peripheral blood stem cell mobilization with granulocyte colony-stimulating factor in a patient with chronic myeloid leukemia achieving a complete cytogenetic remission with dasatinib after failing imatinib.
Journal: Leukemia 20080801
Title: Sequential tyrosine kinase inhibitor therapy: sustained disease remission in Philadelphia-positive erythroleukaemia.
Journal: British journal of haematology 20080801
Title: Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
Journal: Blood 20080801
Title: Dasatinib-induced acute hepatitis.
Journal: Leukemia & lymphoma 20080801
Title: Dasatinib inhibits progenitor cell proliferation from polycythaemia vera.
Journal: European journal of clinical investigation 20080801
Title: Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells.
Journal: Oncogene 20080717
Title: Disease progression in some cancers may be due to low blood levels of targeted therapies.
Journal: Journal of the National Cancer Institute 20080702
Title: Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis.
Journal: FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20080701
Title: Metabolism and disposition of dasatinib after oral administration to humans.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20080701
Title: Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20080701
Title: Isolated central nervous system lymphoid blast crisis in chronic myeloid leukaemia in major molecular remission.
Journal: British journal of haematology 20080701
Title: Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.
Journal: British journal of haematology 20080701
Title: Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080701
Title: Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges.
Journal: Expert opinion on therapeutic targets 20080701
Title: Nilotinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080701
Title: Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib.
Journal: The Journal of biological chemistry 20080627
Title: Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080615
Title: Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080615
Title: [Novel medical treatment modalities in hematology].
Journal: Ugeskrift for laeger 20080609
Title: Initial testing of dasatinib by the pediatric preclinical testing program.
Journal: Pediatric blood & cancer 20080601
Title: HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
Journal: Leukemia research 20080601
Title: Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
Journal: Leukemia research 20080601
Title: The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
Journal: Clinical immunology (Orlando, Fla.) 20080601
Title: Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Journal: Leukemia 20080601
Title: Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
Journal: Leukemia 20080601
Title: Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
Journal: Journal of clinical pharmacy and therapeutics 20080601
Title: Dasatinib therapy for systemic mastocytosis: four cases.
Journal: European journal of haematology 20080501
Title: Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.
Journal: British journal of haematology 20080501
Title: Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
Journal: Cancer research 20080501
Title: Novel chromosomal aberration in Philadelphia negative cells of a patient with chronic myelogenous leukemia treated with dasatinib.
Journal: Leukemia & lymphoma 20080501
Title: Dasatinib suppresses in vitro natural killer cell cytotoxicity.
Journal: Blood 20080415
Title: Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080415
Title: Management of patients with resistant or refractory chronic myelogenous leukemia.
Journal: Oncology (Williston Park, N.Y.) 20080415
Title: A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment.
Journal: Leukemia 20080401
Title: Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.
Journal: Leukemia research 20080401
Title: BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism.
Journal: Leukemia 20080401
Title: Metabolite generation via microbial biotransformations with Actinomycetes: rapid screening for active strains and biosynthesis of important human metabolites of two development-stage compounds, 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non7-yl-methyl]-3-thiophenecarboxylic acid (BMS-587101) and dasatinib.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20080401
Title: Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
Journal: Leukemia & lymphoma 20080401
Title: Therapy options in imatinib failures.
Journal: The oncologist 20080401
Title: The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils.
Journal: Blood 20080315
Title: Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Journal: Cancer chemotherapy and pharmacology 20080301
Title: Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib.
Journal: Blood 20080301
Title: BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
Journal: Blood 20080301
Title: Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN 20080301
Title: BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN 20080301
Title: Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
Journal: Clinical lymphoma & myeloma 20080301
Title: Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Journal: Clinical lymphoma & myeloma 20080301
Title: Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors.
Journal: Clinical lymphoma & myeloma 20080301
Title: In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.
Journal: Blood 20080215
Title: Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML.
Journal: Leukemia research 20080201
Title: Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.
Journal: Blood 20080201
Title: New developments in multitargeted therapy for patients with solid tumours.
Journal: Cancer treatment reviews 20080201
Title: In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines.
Journal: Oncology reports 20080201
Title: IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.
Journal: Molecular cancer therapeutics 20080201
Title: [Research advance on molecular genetics of CML blast crisis].
Journal: Zhongguo shi yan xue ye xue za zhi 20080201
Title: [Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia].
Journal: Ugeskrift for laeger 20080128
Title: Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080115
Title: Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines.
Journal: Breast cancer research and treatment 20080101
Title: American Society of Hematology annual meeting.
Journal: The Lancet. Oncology 20080101
Title: Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20080101
Title: Overcoming kinase resistance in chronic myeloid leukemia.
Journal: The international journal of biochemistry & cell biology 20080101
Title: Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.
Journal: Journal of applied genetics 20080101
Title: Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Journal: Journal of translational medicine 20080101
Title: Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Journal: Hematology. American Society of Hematology. Education Program 20080101
Title: Targeted drugs in chronic myeloid leukemia.
Journal: Current medicinal chemistry 20080101
Title: New strategies in controlling drug resistance in chronic myeloid leukemia.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20071215
Title: Chronic myeloid leukemia. Introduction.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20071215
Title: Leukemia. Q&A highlights.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20071215
Title: Targeted chronic myeloid leukemia therapy: Seeking a cure.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20071215
Title: Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Journal: Blood 20071201
Title: Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib.
Journal: Hematology (Amsterdam, Netherlands) 20071201
Title: Potential targeted therapy options in the management of basal cell subtype of breast carcinoma.
Journal: Human pathology 20071201
Title: Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Journal: Expert opinion on pharmacotherapy 20071201
Title: Viral infection or reactivation in patients during treatment with dasatinib: a call for screening?
Journal: Leukemia & lymphoma 20071201
Title: Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
Journal: Leukemia & lymphoma 20071201
Title: Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825).
Journal: Leukemia & lymphoma 20071201
Title: Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
Journal: Journal of medicinal chemistry 20071115
Title: Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/'triple-negative' breast cancer cell lines growing in vitro.
Journal: Breast cancer research and treatment 20071101
Title: The role of Src in prostate cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20071101
Title: Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation.
Journal: Leukemia 20071101
Title: Characterization of cancer stem cells in chronic myeloid leukaemia.
Journal: Biochemical Society transactions 20071101
Title: Management of Bcr-Abl-positive leukemias with dasatinib.
Journal: Expert review of anticancer therapy 20071101
Title: Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Journal: Haematologica 20071101
Title: Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Journal: Clinical therapeutics 20071101
Title: Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.
Journal: American journal of respiratory and critical care medicine 20071015
Title: Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia.
Journal: Blood 20071015
Title: Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
Journal: Blood 20071001
Title: Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
Journal: European journal of clinical investigation 20071001
Title: American Chemical Society--234th National Meeting. Syntheses of novel compounds and data on novel therapeutics. 19-23 August 2007, Boston, MA, USA.
Journal: IDrugs : the investigational drugs journal 20071001
Title: Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation.
Journal: Leukemia & lymphoma 20071001
Title: [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
Journal: Bulletin du cancer 20071001
Title: New strategies in controlling drug resistance.
Journal: Journal of managed care pharmacy : JMCP 20071001
Title: Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Journal: Cancer 20070915
Title: Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
Journal: The Journal of clinical investigation 20070904
Title: FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Journal: The Journal of clinical investigation 20070904
Title: Leukemia, an effective model for chemical biology and target therapy.
Journal: Acta pharmacologica Sinica 20070901
Title: Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070901
Title: Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070815
Title: The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
Journal: Proceedings of the National Academy of Sciences of the United States of America 20070814
Title: American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 4.
Journal: IDrugs : the investigational drugs journal 20070801
Title: Cancer agents show first-line potential.
Journal: JAMA 20070725
Title: BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Journal: The New England journal of medicine 20070719
Title: L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
Journal: International journal of cancer 20070715
Title: Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
Journal: Cancer 20070715
Title: Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070715
Title: Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion.
Journal: Molecular cancer therapeutics 20070701
Title: Drugs offer new hope for patients with CML who are resistant to imatinib.
Journal: ONS connect 20070701
Title: Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
Journal: Blood 20070615
Title: Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors.
Journal: Oncogene 20070614
Title: BCR-ABL mutant kinetics in CML patients treated with dasatinib.
Journal: Leukemia research 20070601
Title: Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure.
Journal: Haematologica 20070601
Title: Dasatinib: a new step in molecular target therapy.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20070601
Title: [Novel anti-CML agents beyond imatinib].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20070601
Title: Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Journal: Blood 20070515
Title: MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Journal: Blood 20070501
Title: Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Journal: Expert opinion on investigational drugs 20070501
Title: Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy.
Journal: Leukemia & lymphoma 20070501
Title: Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.
Journal: Current hematologic malignancy reports 20070501
Title: Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Journal: Blood 20070415
Title: Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Journal: Molecular cancer therapeutics 20070401
Title: Dasatinib is effective in imatinib-resistant CML.
Journal: The Lancet. Oncology 20070401
Title: The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
Journal: Leukemia & lymphoma 20070401
Title: Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Journal: Blood 20070315
Title: Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Journal: Cancer research 20070315
Title: Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.
Journal: The Lancet. Oncology 20070301
Title: Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.
Journal: Cancer research 20070301
Title: Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Journal: Haematologica 20070301
Title: A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
Journal: Journal of drugs in dermatology : JDD 20070301
Title: With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.
Journal: Journal of the National Cancer Institute 20070207
Title: [Innovation of clinical trials for anti-cancer drugs in Japan--proposals from academia with special reference to the development of novel Bcr-Abl/Lyn tyrosine kinase inhibitor INNO-406 (NS-187) for imatinib-resistant chronic myelogenous leukemia].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20070201
Title: What is new in chronic myeloid leukaemia?
Journal: Scottish medical journal 20070201
Title: Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
Journal: Clinical journal of oncology nursing 20070201
Title: [New horizon of chronic myelogenous leukemia].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20070128
Title: Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
Journal: Blood 20070115
Title: Dasatinib (Sprycel) for CML and Ph + ALL.
Journal: The Medical letter on drugs and therapeutics 20070115
Title: New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Journal: Seminars in hematology 20070101
Title: [Molecular targeting therapy for chronic myeloid leukemia].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20070101
Title: Dasatinib.
Journal: Drugs of today (Barcelona, Spain : 1998) 20070101
Title: New drugs: paliperidone, dasatinib, and decitabine.
Journal: Journal of the American Pharmacists Association : JAPhA 20070101
Title: What's blasting off in CML?
Journal: ONS connect 20070101
Title: Promising new targeted agents in head and neck cancer.
Journal: International journal of radiation oncology, biology, physics 20070101
Title: Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy.
Journal: Acta haematologica 20070101
Title: Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Joseph Brandwein.
Journal: Drugs 20070101
Title: Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring.
Journal: Genome biology 20070101
Title: In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
Journal: Cancer research 20061201
Title: Dasatinib induces a response in malignant thymoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061201
Title: Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20061201
Title: Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Journal: Molecular cancer therapeutics 20061201
Title: Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
Journal: Future oncology (London, England) 20061201
Title: Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061120
Title: 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.
Journal: Journal of medicinal chemistry 20061116
Title: Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
Journal: Clinical colorectal cancer 20061101
Title: Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.
Journal: Blood 20061001
Title: Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20061001
Title: Dasatinib in chronic myelogenous leukemia.
Journal: The New England journal of medicine 20060907
Title: Dasatinib in chronic myelogenous leukemia.
Journal: The New England journal of medicine 20060907
Title: Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML.
Journal: Blood 20060901
Title: Pharmacy benefit spending on oral chemotherapy drugs.
Journal: Journal of managed care pharmacy : JMCP 20060901
Title: Dasatinib.
Journal: Nature reviews. Drug discovery 20060901
Title: Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
Journal: Current hematologic malignancy reports 20060901
Title: Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.
Journal: Blood 20060815
Title: Tyrosine kinase inhibitors: the next generation.
Journal: The Lancet. Oncology 20060801
Title: Glivec and beyond.
Journal: European journal of cancer (Oxford, England : 1990) 20060801
Title: [New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].
Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060801
Title: Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
Journal: Blood 20060701
Title: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Journal: The New England journal of medicine 20060615
Title: Circumventing resistance to kinase-inhibitor therapy.
Journal: The New England journal of medicine 20060615
Title: Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia.
Journal: The New England journal of medicine 20060615
Title: Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.
Journal: Blood 20060601
Title: Impact of genetic diagnostics on drug development strategy.
Journal: Nature reviews. Drug discovery 20060601
Title: Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825.
Journal: Blood 20060601
Title: Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.
Journal: Cancer research 20060601
Title: The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
Journal: Cancer research 20060601
Title: Dasatinib-related alveolar pneumonia responsive to corticosteroids.
Journal: Leukemia & lymphoma 20060601
Title: Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib).
Journal: Molecular pharmacology 20060501
Title: New assignments for multitasking signal transduction inhibitors.
Journal: Molecular pharmacology 20060501
Title: Kinase inhibitors in chronic myelogenous leukemia.
Journal: Clinical advances in hematology & oncology : H&O 20060501
Title: Clinical development of SRC tyrosine kinase inhibitors in lung cancer.
Journal: Clinical lung cancer 20060501
Title: [State of the art in the treatment of chronic leukemias].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20060401
Title: Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
Journal: The American journal of pathology 20060301
Title: Targeted CML therapy: controlling drug resistance, seeking cure.
Journal: Current opinion in genetics & development 20060201
Title: Looking beyond imatinib: next line of targeted drugs for CML shows promise.
Journal: JAMA 20060125
Title: Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
Journal: Cancer research 20060115
Title: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Journal: Cancer research 20060101
Title: Dasatinib: BMS 354825.
Journal: Drugs in R&D 20060101
Title: [Novel inhibitors of Bcr-Abl].
Journal: Postepy higieny i medycyny doswiadczalnej (Online) 20060101
Title: The FDA approves new leukemia drug; expands use of current drug.
Journal: FDA consumer 20060101
Title: Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Journal: Cancer research 20051015
Title: Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20051001
Title: Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20051001
Title: Chronic myelogenous leukemia.
Journal: Clinical journal of oncology nursing 20051001
Title: Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies.
Journal: Leukemia 20050701
Title: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
Journal: Cancer research 20050601
Title: BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia.
Journal: Expert opinion on investigational drugs 20050101
Title: Loss of response to imatinib: mechanisms and management.
Journal: Hematology. American Society of Hematology. Education Program 20050101
Title: Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
Journal: Journal of medicinal chemistry 20041230
Title: Two new agents effective in Gleevec-resistant CML.
Journal: Cancer biology & therapy 20041201
Title: New generation leukaemia drugs are on their way.
Journal: Drug discovery today 20040901
Title: Oral BMS-354825 rescues Gleevec-resistant CML.
Journal: Cancer biology & therapy 20040801
Title: Cancer. Gleevec, chapter two: new leukemia drug aims to overcome resistance.
Journal: Science (New York, N.Y.) 20040716
Title: Overriding imatinib resistance with a novel ABL kinase inhibitor.
Journal: Science (New York, N.Y.) 20040716
Title: Lombardo LJ, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004 Dec 30;47(27):6658-61.
